Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2022-09-14 Major Shareholding Noti…
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to changes in voting rights, shareholder details, and thresholds crossed. This structure is characteristic of regulatory filings concerning significant ownership changes. The RNS Number and reference to the FCA confirm its regulatory nature. This directly maps to the definition of Major Shareholding Notification (MRQ).
2022-09-14 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-year Report' and 'Business Update and Interim Report for the six months ended 30 June 2022'. It contains detailed financial statements, revenue analysis, cost of sales, and operational reviews for the interim period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled as an 'RNS Number' and contains a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership thresholds. The content details the shareholder (Jupiter Fund Management PLC), the issuer (Shield Therapeutics PLC), the date the threshold was crossed, and the resulting percentage of voting rights (4.68%). This directly corresponds to the definition of a Major Shareholding Notification.
2022-09-01 English
Launch of new corporate brand and website
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 8321X' and contains information typical of a regulatory news service announcement. The content announces the 'Launch of new corporate brand and website' and provides contact details and boilerplate information about the company and its product. Crucially, the end of the document explicitly states: 'This information is provided by Reach, the non-regulatory press release distribution service of RNS...' and 'Reach announcements are identified with an orange label...'. Since this is a non-regulatory press release distributed via the RNS system, and it does not fit the specific definitions for ER, DIV, CAP, etc., it falls best under the general 'Regulatory Filings' fallback category (RNS), as it is a formal announcement distributed through the regulatory channel, even if marked as non-regulatory content by the distributor (Reach). Given the options, RNS is the most appropriate catch-all for formal announcements distributed via the RNS platform that aren't covered by more specific codes like ER or DIV.
2022-09-01 English
Total Voting Rights Update
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the header 'RNS Number : 7971X' and explicitly states it is providing information via 'RNS, the news service of the London Stock Exchange.' The content details the 'Total Voting Rights Update' as required by the FCA's Disclosure and Transparency Rule 5.6.1, confirming the total number of issued shares. This type of mandatory, periodic regulatory disclosure that doesn't fit a more specific category (like 10-K, ER, or DIRS) is best classified as a general Regulatory Filing (RNS). The document length is short (3907 chars), but it is a direct announcement of data rather than an announcement *about* another report, making RNS more appropriate than RPA.
2022-08-31 English
Notice of Interim Results
Report Publication Announcement Classification · 99% confidence The document is a formal announcement disseminated via RNS (RNS Number: 7694X) from Shield Therapeutics plc. The core content is a 'Notice of Interim Results' which explicitly states that the company 'will announce its interim results for the six months ended 30 June 2022 on Thursday 8 September 2022.' It then details the schedule for an analyst briefing and an investor presentation related to these upcoming results. Since the document itself is not the comprehensive Interim Report (IR) but rather an announcement about the *timing* and *format* of the results release and subsequent investor engagement, it fits the definition of a Report Publication Announcement (RPA). The document length (4850 chars) is relatively short, supporting the idea that it is an announcement rather than the full financial report.
2022-08-31 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.